BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31150604)

  • 21. Bone involvement in two cases of thoracic primary cutaneous diffuse large B-cell lymphoma, leg type.
    Lipowicz S; Beylot-Barry M; Choquet S; Maksud P; Vergier B; Albertini AF; Frances C; Barete S
    Eur J Dermatol; 2011; 21(5):744-9. PubMed ID: 21700538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
    Pedrosa L; Fernández-Miranda I; Pérez-Callejo D; Quero C; Rodríguez M; Martín-Acosta P; Gómez S; González-Rincón J; Santos A; Tarin C; García JF; García-Arroyo FR; Rueda A; Camacho FI; García-Cosío M; Heredero A; Llanos M; Mollejo M; Piris-Villaespesa M; Gómez-Codina J; Yanguas-Casás N; Sánchez A; Piris MA; Provencio M; Sánchez-Beato M
    Sci Rep; 2021 Jan; 11(1):1886. PubMed ID: 33479306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report].
    Zhong GC; Yu XN; Li J; Chen CY
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):258. PubMed ID: 37356991
    [No Abstract]   [Full Text] [Related]  

  • 24. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
    Lenz G; Davis RE; Ngo VN; Lam L; George TC; Wright GW; Dave SS; Zhao H; Xu W; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Chan WC; Staudt LM
    Science; 2008 Mar; 319(5870):1676-9. PubMed ID: 18323416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells.
    Felcht M; Heck M; Weiss C; Becker JC; Dippel E; Müller CS; Nashan D; Sachse MM; Nicolay JP; Booken N; Goerdt S; Klemke CD
    Br J Dermatol; 2012 Aug; 167(2):348-58. PubMed ID: 22512270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
    Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.
    Kersten MJ; Kraan W; Doorduijn J; Bromberg J; Lam K; Kluin PM; van der Holt BJ; Spaargaren M; Pals ST
    Blood Cancer J; 2014 Dec; 4(12):e266. PubMed ID: 25501023
    [No Abstract]   [Full Text] [Related]  

  • 29. Mutation analysis of NF-κB signal pathway-related genes in ocular MALT lymphoma.
    Liu F; Karube K; Kato H; Arita K; Yoshida N; Yamamoto K; Tsuzuki S; Kim W; Ko YH; Seto M
    Int J Clin Exp Pathol; 2012; 5(5):436-41. PubMed ID: 22808296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type.
    Espinet B; García-Herrera A; Gallardo F; Baró C; Salgado R; Servitje O; Estrach T; Colomo L; Romagosa V; Barranco C; Serrano S; Campo E; Pujol RM; Solé F
    Histol Histopathol; 2011 Feb; 26(2):213-21. PubMed ID: 21154235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
    Fujii K; Inagaki A; Masaki A; Sugiura M; Suzuki T; Ishida T; Kusumoto S; Iida S; Inagaki H
    Ann Hematol; 2024 Jun; 103(6):2041-2050. PubMed ID: 38411628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
    Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
    Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant
    Deng AL; Kim YR; Lichtenstein EA; O'Connor OA; Deng C
    Haematologica; 2017 Jul; 102(7):e275-e277. PubMed ID: 28341730
    [No Abstract]   [Full Text] [Related]  

  • 34. A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma.
    Dong G; Chanudet E; Zeng N; Appert A; Chen YW; Au WY; Hamoudi RA; Watkins AJ; Ye H; Liu H; Gao Z; Chuang SS; Srivastava G; Du MQ
    Clin Cancer Res; 2011 Mar; 17(6):1440-51. PubMed ID: 21266526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired CARD11 mutation promotes BCR independence in Diffuse Large B Cell Lymphoma.
    Caeser R; Walker I; Gao J; Shah N; Rasso-Barnett L; Anand S; Martin JE; Hodson DJ
    JCO Precis Oncol; 2021; 5():145-152. PubMed ID: 33542970
    [No Abstract]   [Full Text] [Related]  

  • 36. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
    Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.
    Choi J; Phelan JD; Wright GW; Häupl B; Huang DW; Shaffer AL; Young RM; Wang Z; Zhao H; Yu X; Oellerich T; Staudt LM
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6092-6102. PubMed ID: 32127472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
    Grange F; Beylot-Barry M; Courville P; Maubec E; Bagot M; Vergier B; Souteyrand P; Machet L; Dalac S; Esteve E; Templier I; Delaporte E; Avril MF; Robert C; Dalle S; Laroche L; Delaunay M; Joly P; Wechsler J; Petrella T
    Arch Dermatol; 2007 Sep; 143(9):1144-50. PubMed ID: 17875875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
    Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
    Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
    Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.